Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients
Sponsor: University of Bologna
Terminated
The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene)
Other terminated trials from University of Bologna
Other Peripheral T-cell Lymphoma trials with similar outcome
A PHASE2 clinical study on Peripheral T-cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by University of Bologna and has accumulated 9 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Bologna
For direct contact, visit the study record on ClinicalTrials.gov .